Morison Industries PLC
NNSENG:MORISON10.40
NGN
0.00
(0.00%)
ISIN
NGMORISON000
Return %
Stock
S&P 500
1Y
222.98
14.20
3Y
307.84
81.12
5Y
450.26
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Adesoji Akinola Oladejo
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Lagos Nigeria
- Similar Companies
- Business
- Morison Industries PLC is a Nigeria-based healthcare, hygiene, and chemical manufacturing company engaged in the production, importation, marketing, and distribution of pharmaceuticals, medical consumables, and sanitation formulations. Founded in 1955 and headquartered in Ikeja, Lagos, Nigeria, the company operates primarily within the Nigerian domestic market with distribution networks extending across the West African sub-region. Morison Industries categorizes its commercial operations across key product lines: hygiene and disinfectant formulations, including its flagship Morigad brand of antiseptic liquids, hospital-grade germicides, surface disinfectants, liquid detergents, antibacterial soaps, and hand sanitizers; pharmaceutical and healthcare products, comprising generic oral analgesics, topical ointments, anti-infectives, and over-the-counter therapeutic remedies; medical consumables and hospital supplies, such as surgical dressings, sterile bandages, diagnostic test kits, suture materials, and clinical consumables supplied to healthcare institutions, private hospitals, laboratories, and retail pharmacies; and industrial and agro-allied chemical formulations, including institutional cleaning agents, pest management solutions, and specialized contract toll manufacturing services for commercial clients. In recent developments, Morison Industries has pursued strategic restructuring and operational revitalization programs to address macroeconomic headwinds, enhance liquidity, and improve plant capacity utilization. The company has engaged in capital reorganization initiatives to strengthen working capital, modernized production and packaging lines at its Ikeja facility to ensure compliance with updated Good Manufacturing Practice (GMP) standards under the National Agency for Food and Drug Administration and Control (NAFDAC), expanded third-party contract manufacturing and toll-blending partnerships, broadened its regional retail and institutional distribution agreements, and executed corporate governance and management realignments focused on cost rationalization, domestic raw material sourcing, and product portfolio optimization.